StoneX Group’s Mereo BioPharma MREO Stock Holding History

StoneX Group’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-36,873	Closed	-$12.2K	–	1530
2026 Q1	$12.2K	Buy	+36,873	New	+$15.8K	﹤0.01%	845

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

StoneX Group's MREO Position: Q2 2026 in Review

StoneX Group sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 36,873 shares — an estimated $12.2K sold.

StoneX Group first reported a position in MREO in Q1 2026 and held it in 1 quarter. The position peaked at $12.2K in Q1 2026. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

StoneX Group reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
StoneX Group sold 36,873 Mereo BioPharma shares in Q2 2026, an estimated $12.2K.
StoneX Group first reported a position in Mereo BioPharma in Q1 2026 and held it in 1 quarter.
StoneX Group's Mereo BioPharma position peaked at $12.2K in Q1 2026.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.